Results 131 to 140 of about 34,445,663 (284)
Therapeutic Impact of GLP‐1 Receptor Agonists on Parkinson's Disease: A Scoping Review
Neurology and Clinical Neuroscience, EarlyView.ABSTRACT No disease‐modifying treatment exists for Parkinson's disease (PD). Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have gained attention as promising candidates for neuroprotection, given documented expression of GLP‐1 receptors within the central nervous system and the contribution of brain insulin resistance to dopaminergic ...
João Pedro Henriques +4 more
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective SURMOUNT‐REAL UK will evaluate the effectiveness of tirzepatide when offered in addition to standard‐of‐care (SoC) in adults with Class I obesity (BMI ≥ 30 and ≤ 34.9 kg/m2) and without diabetes in a UK primary care setting. Methods A 5‐year, phase 4, multicenter, open‐label, pragmatic randomized clinical trial is enabled through ...
Martin K. Rutter +14 more
wiley +1 more source
The glucagon-like peptide-1 receptor-agonist semaglutide
, 2019 Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented.
Juhl, Christian Rimer +3 more
core +1 more source
GLP-1 agonists in the treatment of chronic kidney disease in type 2 diabetes and obesity
The Journal of Clinical InvestigationGlucagon-like peptide-1 (GLP-1) was initially considered to be a hormone with a predominant role in regulating glucose metabolism by inducing insulin secretion, reducing glucagon secretion, and ameliorating insulin resistance, with the last effect being ...
Mark E. Cooper, Daniël H. van Raalte
doaj +1 more source
How the Sea Salt Chocolate Cookie Became a Thing: The Role of Flavor Pairing in Obesity
Obesity, EarlyView.Proposed framework illustrating how flavor pairing and multisensory flavor architecture may sustain hedonic eating through enhanced palatability, reward preservation, delayed sensory‐specific satiety, and post‐ingestive signaling, thereby promoting excess energy intake and obesity risk.
Mohammed Ayyad, Eugene Kim
wiley +1 more source
Obesity, EarlyView.ABSTRACT Objective Incretin‐based obesity therapies (IBTs), especially GLP‐1 receptor agonists (GLP‐1 RAs), effectively treat obesity and improve comorbidities. However, their impact on energy metabolism is unclear. A recent case of acute generalized muscle weakness in a patient with mitochondrial myopathy after tirzepatide exposure raises concerns ...
Bryn Falahee +2 more
wiley +1 more source
Weight Self‐Stigma and Food Noise During Post‐Metabolic Bariatric Surgery Weight Stability
Obesity, EarlyView.ABSTRACT Objective Food noise has been studied with GLP‐1‐based therapies, but not with metabolic bariatric surgery (MBS), despite shared mechanisms. Data on food noise beyond initial weight loss are limited, and weight self‐stigma (WSS), which links to poorer weight outcomes and risky behaviors after MBS, may relate to higher food noise, especially ...
Dale S. Bond +8 more
wiley +1 more source
Glucagon-like peptide-1 receptor agonists: a systematic review of comparative effectiveness research
, 2017 Philip A Levin,1 Hiep Nguyen,2 Eric T Wittbrodt,2 Seoyoung C Kim3 1Bay West Endocrinology Associates, Baltimore, MD, 2Health Economics and Outcomes Research, AstraZeneca, Wilmington, DE, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Department
Nguyen H, Kim SC, Levin PA, Wittbrodt ET
core
Otolaryngology–Head and Neck Surgery, EarlyView.Abstract Objective To evaluate glucagon‐like peptide 1 receptor agonists for obstructive sleep apnea compared with controls. Data Sources CINAHL, Cochrane Library, PubMed, and Scopus. Review Methods A PRISMA‐compliant search was conducted from database inception through October 2025.
Cali Loblundo +3 more
wiley +1 more source